Good News丨COSMOS’s two subsidiaris passed FDA on-site audit with no “483” defect

Recently COSMOS's two wholly-owned subsidiaries, SINOBEST Cosmeceutical Technology Co., Ltd. (SINOBEST) and Ma'anshan COSMOS Chemical Co., Ltd. (Ma'anshan COSMOS) received a formal notice from FDA (U.S. Food and Drug Administration): They passed the cGMP (Current Good Manufacture Practices) on-site inspection with NAI (No Action Indicated) and zero  "483" defect.

After 12-day cGMP inspection to SINOBEST and Ma'anshan COSMOS respectively from August 19 to 30, 2024, FDA inspectors confirmed that both companies had established a sound cGMP management system, allocated the corresponding technical management personnel, introduced complete production and inspection facilities, and owned complete document system, and intact production & quality management system.

COSMOS's passing FDA on-site inspection fully demonstrates its excellent capability of quality management and full recognition of its high-standard manufacturing specification by the international authoritative agency. The COSMOS team will continue to uphold this original aspiration, work in a down-to-earth manner, thoroughly implement the quality policy. We will maintain the regular management of cGMP, adhere to the continuous improvement of the quality management system, and strictly ensure the quality of personal care products. We are committed to ongoing technological innovation and management reform to enhance our international competitiveness, thereby further enabling our products to establish a foothold in the global market and set sail for new horizons.